Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Vladimir-Prelog-Weg 3, HCI H303, 8093, Zurich, Switzerland.
Angiogenesis. 2021 Feb;24(1):67-82. doi: 10.1007/s10456-020-09743-9. Epub 2020 Sep 12.
Lymphatic and blood vascular endothelial cells (ECs) share several molecular and developmental features. However, these two cell types possess distinct phenotypic signatures, reflecting their different biological functions. Despite significant advances in elucidating how the specification of lymphatic and blood vascular ECs is regulated at the transcriptional level during development, the key molecular mechanisms governing their lineage identity under physiological or pathological conditions remain poorly understood. To explore the epigenomic signatures in the maintenance of EC lineage specificity, we compared the transcriptomic landscapes, histone composition (H3K4me3 and H3K27me3) and DNA methylomes of cultured matched human primary dermal lymphatic and blood vascular ECs. Our findings reveal that blood vascular lineage genes manifest a more 'repressed' histone composition in lymphatic ECs, whereas DNA methylation at promoters is less linked to the differential transcriptomes of lymphatic versus blood vascular ECs. Meta-analyses identified two transcriptional regulators, BCL6 and MEF2C, which potentially govern endothelial lineage specificity. Notably, the blood vascular endothelial lineage markers CD34, ESAM and FLT1 and the lymphatic endothelial lineage markers PROX1, PDPN and FLT4 exhibited highly differential epigenetic profiles and responded in distinct manners to epigenetic drug treatments. The perturbation of histone and DNA methylation selectively promoted the expression of blood vascular endothelial markers in lymphatic endothelial cells, but not vice versa. Overall, our study reveals that the fine regulation of lymphatic and blood vascular endothelial transcriptomes is maintained via several epigenetic mechanisms, which are crucial to the maintenance of endothelial cell identity.
淋巴管和血管内皮细胞(EC)具有一些共同的分子和发育特征。然而,这两种细胞类型具有不同的表型特征,反映了它们不同的生物学功能。尽管在阐明淋巴管和血管内皮细胞在发育过程中如何在转录水平上被特化方面取得了重大进展,但在生理或病理条件下控制其谱系身份的关键分子机制仍知之甚少。为了探索维持 EC 谱系特异性的表观基因组特征,我们比较了培养的匹配人真皮淋巴管和血管内皮细胞的转录组图谱、组蛋白组成(H3K4me3 和 H3K27me3)和 DNA 甲基化组。我们的研究结果表明,血管谱系基因在淋巴管内皮细胞中表现出更“抑制”的组蛋白组成,而启动子处的 DNA 甲基化与淋巴管与血管内皮细胞的差异转录组相关性较小。荟萃分析确定了两个转录调节因子,BCL6 和 MEF2C,它们可能控制内皮谱系特异性。值得注意的是,血管内皮谱系标志物 CD34、ESAM 和 FLT1 和淋巴管内皮谱系标志物 PROX1、PDPN 和 FLT4 表现出高度差异的表观遗传特征,并以不同的方式对表观遗传药物治疗做出反应。组蛋白和 DNA 甲基化的扰动选择性地促进了淋巴管内皮细胞中血管内皮标志物的表达,但反之则不然。总体而言,我们的研究表明,淋巴管和血管内皮细胞转录组的精细调控是通过几种表观遗传机制维持的,这对于维持内皮细胞身份至关重要。